A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases.
GX Acquisition Corp has entered into a definitive agreement with Celularity.
News from Celularity:
Celularity Announces Full Year 2024 Operating and Financial Results
Read More Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and financial results for…
Continue Reading Celularity Announces Full Year 2024 Operating and Financial Results
Celularity Announces Full Year 2024 Operating and Financial Results
Read More Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and financial results for…
Continue Reading Celularity Announces Full Year 2024 Operating and Financial Results
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Read More Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, welcomes action…
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Read More Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, welcomes action…
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Read More Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced a key publication in the April 4, 2025, issue of the prestigious peer-reviewed journal Frontiers in Immunology, the…
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Read More Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced a key publication in the April 4, 2025, issue of the prestigious peer-reviewed journal Frontiers in Immunology, the…
[fts_twitter twitter_name=celularity tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]